Observational studyBMC infectious diseases2026
Efficacy of glucocorticoid therapy for severe jaundice patients with drug-induced liver injury or hepatitis B virus-related acute-on-chronic liver failure: a respectively observational study.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe success in managing jaundice depends on identifying underlying cause and implementing effective treatment. In this study, we aimed to identify the etiologies of severe jaundice and evaluated the efficacy of glucocorticoids (GCs) in drug-induced liver injury (DILI) and hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF).
methodsThis is a retrospective study of 460 patients with total bilirubin (TBIL) exceeding 85.5 µmol/L from November 2017 to November 2023. The prognosis of patients with DILI or HBV-ACLF receiving GC therapy or non-GC therapy was evaluated.
resultsHBV infection and DILI were the two most common causes of sever jaundice (36.96% and 22.17%, respectively). In DILI patients, the time taken for peak TBIL levels to decrease by half and to return to normal in the GC therapy group were significantly shorter compared to that in the non-GC therapy group (6 ± 3 vs. 9 ± 4 days, P = 0.006; 32 ± 10 vs. 42 ± 15 days, P = 0.006, respectively) after balancing the baseline parameters using the propensity score matching (PSM) method. Whether in the overall HBV-ACLF population with TBIL ≥ 85.5 µmol/L or in the subgroup with TBIL ≥ 171 µmol/L, the 90-day mortality was significantly lower in the GC group than that in non-GC group (17.9% vs. 56.3%, P = 0.009; 19.4% vs. 60.0%, P = 0.003, respectively). In addition, GC therapy was identified as an independent predictor for mortality in HBV-ACLF patients with TBIL ≥ 171 µmol/L (Hazard Ratio 0.059, 95% confidence interval 0.012–0.284, P < 0.001).
conclusionGC therapy may be beneficial for DILI patients and specific HBV-ACLF patients with severe jaundice. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.